RALTEGRAVIR 1200 mg ONCE DAILY AS MAINTENANCE THERAPY IN VIROLOGICALLY SUPPRESSED HIV-1 INFECTED ADULTS: QDISS OPEN-LABEL TRIAL

Nolwenn Hall  
Public health center

Clotilde Allavena  
CHU Nantes

Christine Katlama  
Pitié-Salpêtrière University Hospital

Alexandra Jobert  
CHU Nantes

Jean-Michel Molina  
Université de Paris Diderot

Eric Cua  
Hôpital de l'Archet, Centre Hospitalier de Nice

Firouzé Bani-Sadr  
University of Reims

Laurent Hocqueloux  
CHR d’Orléans

Claudine Duvivier  
Necker-Pasteur Infectiology Centre

Dominique Merrien  
CHD Vendee, La Roche sur yon

Hitoto Hikombo  
Le Mans General Hospital

Elisabeth André-Garnier  
Nantes University

Aurélie Gaultier  
Direction de la recherche

François Raffi (✉️ francois.raffi@wanadoo.fr)  
CHU Nantes

Research
Abstract

Background: Raltegravir (RAL) has favorable tolerability and safety profile, with few and manageable drug interactions. The use of RAL 1200 mg once daily (qd) for first-line therapy is well established. We assessed efficacy and safety of RAL 1200 mg qd, as part of triple cART, for maintenance strategy.

Methods: The QDISS trial (NCT03195452) was a 48-week multicenter, single-arm, open-label study designed to evaluate the ability of 2 NRTIs + RAL 1200 mg qd to maintain virological suppression in HIV-1 infected subjects on a stable cART with 2 NRTIs and a third agent for at least 6 months. The primary endpoint was the proportion of participants with HIV-1 RNA <50 copies/mL at week 24, by the FDA snapshot algorithm.

Results: Of 100 participants 91% maintained viral suppression (95% CI: 83.6-95.8) at week 24 and 89% (81.2-94.4) at week 48. At week 24, there was one virological failure, without emergence of resistance-associated mutation and 10 participants had discontinued, 4 because of adverse events (AEs). Over 48 weeks, 7 AEs of grade 3-4 were reported, one possibly study-drug related (spontaneous abortion). BMI remained stable regardless of previous therapy or baseline BMI category. Over 48 weeks, total cholesterol (p=0.023) and LDL-cholesterol (p=0.009) decreased, lifestyle and ease subscale significantly improved (p=0.04). The quality of life and Patients Reported Outcomes (PROs) also improved at W12 (p=0.007).

Conclusion: RAL 1200 mg qd as part of a maintenance triple therapy showed a high efficacy in virologically suppressed HIV-1 infected subjects, with good safety profile and improved lipid profile and patient reported outcomes.

Trial registration = clinical trials.gov NCT03195452 and EudraCT 2016-003702-13

Background

As viral suppression is achieved in most people living with HIV (PLWHIV) with currently recommended regimens, HIV treatment goals has shifted towards a durable viral suppression and an optimal long-term tolerability of cART with regimens that are lifestyle compatible. ¹ This is even more relevant in the context of Western countries, where approximately half of PLWHIV are older than 50 years, with a growing tribute of age-related and non-HIV disease-related comorbidities, associated medications, and possible effects of long-term chronic exposure to antiretroviral therapy (cART). ² Integrase strand transfer inhibitors (INSTIs), given their high antiviral potency and their favorable safety profile are now recommended, as the cornerstone of combination ART (cART), in all HIV infected individuals. ³ Although bictegravir and dolutegravir are preferred among the INSTI class, there are not free of some concerns, such as weight gain, emergence of metabolic abnormalities and neuropsychiatric adverse events. Raltegravir (RAL), the first INSTI, has high virological potency together with low drug-drug interaction, good safety profile, such as lipid, inflammation and bone parameters, ⁴ but the twice-per-day (bid) dosing was a real constraint in the era of treatment simplification. In 2017, a new formulation of RAL 1200mg (2 x 600mg tablets) qd
showed non inferior efficacy and similar safety to RAL 400mg bid for previously untreated HIV-1 patients, in combination with other antiretroviral agents. As no study has yet assessed the efficacy of a switch to RAL 1200 mg qd in patients virologically suppressed, we aimed, in this open-label, single-arm study, to assess the capacity of RAL 1200 mg qd combined with 2 NRTIs to maintain virological success in patients virologically suppressed.

Methods

Study design and participants

QDISS study was a 48 weeks open-label, single-arm, prospective study, conducted in 17 clinical sites in France, designed to evaluate the ability of 2 nucleoside reverse transcriptase inhibitors (NRTIs) in association with RAL qd to maintain virological suppression in HIV-1 infected adults receiving a stable therapy with 2 NRTIs (TDF/FTC, TAF/FTC or ABC/3TC) and a third agent (including RAL 400mg bid but less than 30% of the total cohort), for at least 6 months. Adults aged 18 years or older were eligible if they had plasma HIV-1 RNA < 50 copies/mL for at least 6 months with no more than one blip (between 50 and 200 copies/mL) and no prior virological failure on INSTI or non-nucleoside reverse transcriptase inhibitor-based cART or on NRTI(s) only-therapy. Additional inclusion criteria included absence of resistance to any antiretroviral drug except E138A/G/K/Q/R/S or V179D in blood HIV-RNA or DNA, aspartate and alanine aminotransferase concentration below five times the upper limit of normal, haemoglobin >8g/dl, platelet count >50 000/mm³, estimated glomerular filtration rate by MDRD equation >50mL/min. Women of childbearing potential had to have a negative pregnancy test at screening and to accept the use of contraceptive methods during the study. All participants had an indication to change current their current triple cART for intolerance or prevention of toxicity, or presence of comorbidity justifying change of the 3rd agent, or management of drug-drug interaction, or for patient’s request to simplify or to improve regimen convenience. Patients with chronic hepatitis B infection were allowed in the study if their treatment included TDF or TAF.

Ethical considerations

The study was conducted according to Good Clinical Practice. The protocol was approved by the Ethics Committee of Est III (17.04.06), and authorized by the French National Agency for the Safety of Medicines (ANSM 170133A-41). All participants gave written informed consent. The study was registered with ClinicalTrial.gov (NCT03195452).

Study procedures

After enrolment, participants switched to RAL 1200 mg qd, while maintaining the same background 2 NRTIs. Participants were evaluated at baseline, weeks 4, 12, 24, 36, and 48. At all study visits,
assessments were done for symptom-directed physical examinations, weight, adverse events and concomitant medications, and symptom-directed physical examinations were done. Laboratory tests included haematological analysis, serum chemistry and measures of plasma HIV-1 RNA at each visit, fasting glucose and lipid parameters and CD4 and CD8 cell counts at baseline, weeks 36 and 48. Protocol-defined virological failure (PDVF) was occurrence of 2 consecutive HIV-1 RNA ≥50 copies/mL, the second specimen being taken within 1 to 4 weeks. Genotypic resistance testing was performed in case of PDVF on the confirmatory sample and interpreted following the ANRS algorithm for drug resistance-associated mutations, version 27 (http://www.hivfrenchresistance.org). Adherence was assessed by visual scale, at day 0, weeks 24 and 48. Treatment satisfaction was assessed using two versions of the revised HIV Treatment Satisfaction Questionnaire (HIVTSQ): the HIVTSQs (status version) at baseline, week 24 and 48 and the HIVTSQc (change version) at week 24. 6,7 Two subscale measured general satisfaction/clinical and lifestyle/ease satisfaction. The HIVTSQs measured change in within-participant treatment satisfaction over time, a higher score indicating greater improvement in treatment satisfaction (total treatment score ranging from 0 to 66). The HIVTSQc compared participants' views of their current RAL 1200 md qd-including therapy with their prior treatment (score range from -33 to 33). Health-related quality of life was assessed by the PROQOL-HIV self-administered questionnaire, 8 at day 0, weeks 12 and 48.

Study endpoints

The primary endpoint was the proportion of participants with HIV-1 RNA <50 copies/mL at week 24, by the US FDA snapshot algorithm. This endpoint was set at W24 in order to discuss the possibility to halt the study is the lower 95% CI of the success rate was < 80%. Secondary endpoints were safety and tolerability, virological suppression at week 48, emergence of resistance mutations in case of PDVF, adherence, patient satisfaction, quality of life and patient reported outcomes (PROs).

Statistical analysis

A sample size of 94 patients was required to give a 85% probability of rejecting a baseline response rate of 80% with an exact 5% one-sided significance test when the true response rate is 90%. To take into account patients with consent withdrawal or lost to follow-up (5%), 100 patients had to be enrolled. All patients who received at least one dose of study medication were included in the analysed. No data imputation was performed for secondary endpoint analysis. Baseline variables were described, for all patients, by numbers and percentages for categorical variables and means and standard deviation (sd) for quantitative variables. The proportion of patients with plasma HIV-1 RNA <50 copies/mL, by the US FDA snapshot algorithm, at week 24 was estimated with 95% exact confidence interval. Changes in biological parameters or questionnaire scores were analysed using paired Student's tests. All analyzes were conducted with software R v3.6.0 (R Foundation for Statistical Computing, Vienna, Austria).
Results

From November 2017 to April 2019, 100 subjects were enrolled out of 122 screened individuals, in 17 centers (Figure). Participants’ baseline characteristics are shown in Table. At screening, 18% of participants were receiving a single tablet regimen. Reason for switching their current cART were intolerance or prevention of toxicity in 34% of participants, presence of comorbid condition justifying change of the 3rd agent in 13%, drug-drug interactions in 4% and patient's request in 52%. The proportion of patients who maintained HIV-1 RNA <50 copies/mL in the ITT analysis was 91% (95% CI: 83.6-95.8) at week 24, and 89% (81.2-94.4) at week 48. Overall, only one subject experienced PDVF, at week 24, with plasma HIV-1 RNA of 69,000 and 290 copies/mL on first and confirmatory samples, respectively. On confirmatory sample, there was no emergence of resistance-associated mutation to RAL or NRTIs on genotype testing. Over the 48 weeks of the study, 10 treatment discontinuations occurred for reasons other than PDVF (consent withdrawal, n=4, major violation of entry criteria, n=1, pregnancy, n=1, adverse event, n=4). Thus, the success rate of the strategy was 94.7% (95% CI=88.0-98.3) at week 48.

During the total 48 weeks follow-up, a total of 7 adverse events of grade 3-4 were reported, one possibly related to study drug (spontaneous miscarriage at week 8); 4 of these 7 events were classified as serious (acute HCV infection (1), traumatic bone fracture (1), hematemesis (1), miscarriage (1)). Most frequent AEs, occurring in >10% of participants, were gastrointestinal, musculoskeletal, neuropsychiatric disorders, infections and infestations, and respiratory disorders. Reasons for discontinuation because of treatment-related adverse events were gastro-intestinal side effects (n=2, at week 1 and week 4), gastrointestinal disorder and headache (n=1, at week 6), insomnia, nightmare and arthralgias (n=1, at week 4). BMI remained stable (mean change at W48: 0.15 (±1.23) p= 0.28) regardless of previous therapy (RAL or ARV therapy without RAL) or baseline BMI category. Mean total cholesterol and LDL-cholesterol significantly decreased at W48 (-0.21 mmol/L (±0.84), p=0.023; and -0.19mmol/l (±0.66) p=0.009, respectively). There were no significant changes in triglycerides, HDL-cholesterol and glycaemia at week 48 (mean change: -0.08 (±0.67), p=0.3; 0.01 (±0.26), p=0.61, and 0.22 (±1.03), p=0.081, respectively). Renal parameters were unchanged. Median increase in CD4 cell count at week 48 was 50 cells/mm^3 (IQR: 33 to 142; p<0.001).

Adherence to cART was high (97% intake) and stable throughout the 48 weeks follow-up. At baseline, patient global satisfaction (evaluated by the HIVTSQs) was high and remained unchanged until week 48 (mean change = 0.81 ±9.06) p=0.42). The lifestyle and ease subscale significantly improved between baseline and week 48 (mean change = 0.88 ±3.86); p=0.04. Participants mostly preferred the new regimen, with a total satisfaction change score (HIVTSQc) of 21.3 (±11.79) at week 24. The quality of life and PROs, improved from baseline to week 12 with total score of 47/100 (±15.10) and 50/100 (±14.46) respectively (p=0.007). There was also improvement in the body change dimension (p=0.034), and the treatment impact dimension (p=0.001). No significant difference was observed for other PROs, and between baseline and week 48, for any PRO.

Discussion
Our study showed the high efficacy and safety of switching to a triple therapy based on 2 NRTIs plus RAL 1200mg qd in virologically suppressed patients. At both weeks 24 and 48, maintenance of HIV-1 RNA <50 copies/mL by FDA snapshot analysis was around 90% with the lower margin of 95% CI above the predefined 80% value. RAL 1200 mg qd demonstrated non-inferiority to RAL 400 mg bid, each combined with emtricitabine and tenofovir disoproxil fumarate in previously untreated HIV-1 patients. Despite high virological efficacy, irrespective of baseline viral load, excellent tolerability and safety profile, and low potential for drug interactions, the small risk of resistance emergence (0.2% to 1.4% of patients in RAL 400 mg bid studies, and in 0.9% of patients with RAL 1200 mg qd, at week 96) has led to prefer more recent INSTIs, namely bictegravir and dolutegravir for first-line cART. In virologically suppressed patients, bictegravir-based and dolutegravir-based combinations have also demonstrated very high efficacy and good safety. The SWITCHMRK and SPIRAL studies enrolled patients having sustained virological suppression on ritonavir-boosted protease inhibitor-based therapy with or without prior virological failure and demonstrated that in those with no history of virological failure, switching to RAL 400 mg bid, while continuing background therapy, was associated with > 90% rate of maintenance of virological suppression. No INSTI resistance was evidenced after 48 weeks of switch to RAL 400 mg bid in the SPIRAL study. Our study is the first to show the high efficacy of switching to RAL 1200 mg qd plus 2 NRTIs in virologically suppressed patients with no history of prior virological failure to NRTI-based regimens. Overall, strategy success of the 2 NRTI plus RAL 1200 mg qd switch was 95% at week 48, with only 1% of virological failure, concomitant with a poor transient non-adherence without emergence of resistance, and 4% of discontinuation for low grade adverse events. Of note, there was only 1 case (1%) of discontinuation for neuropsychiatric disorder. Discontinuation of RAL bid because of neuropsychiatric adverse events has been reported to be < 1%. This is lower than the rate of discontinuation for neuropsychiatric adverse events with dolutegravir plus 2 NRTIs, that has been reported between 1.7% and 6% at 1 year. In addition, there was no significant weight or BMI changes after RAL 1200 mg qd switch and fasting lipid total cholesterol and LDL-cholesterol improved, confirming the neutral metabolic profile of RAL compared to protease inhibitors or TAF-containing regimens. Issues on weight gain increase have been recently raised following bictegravir or dolutegravir initiation, especially in previously untreated persons but also in the setting of switch for maintenance, while RAL has minimal effect. No BMI change was seen in the subgroup of patients switched form a non-RAL regimen, adding further evidence of differentiation of RAL within the INSTI class. This should be interpreted cautiously as, in our study, participants were mainly Caucasian male with a normal baseline BMI. Improvement in PROs and of quality of life are particularly noteworthy, in the context of chronic asymptomatic disease, in relation to the good tolerability of RAL 1200 mg qd, even though this regimen implies 3 pills once a day. Participants also mostly preferred their new regimen.

Our study have some limitations, including the absence of a control group, which in terms of impact on metabolic parameters (lipids, glycemia, BMI) may limit the interpretation of the observed changes over time. Although absence of a comparator group precludes any formal conclusion, efficacy rate of 89% is at the same level as for other INSTIs as maintenance switch strategy. Second, the magnitude of patients’
satisfaction might have been biased by the open label design of the study and by the request for a change of cART by patients themselves in 52% of cases. Also, because of the diversity of prior cART regimen, we could not assess changes in PROs according to previous regimen.

In conclusion, results of our study position RAL 1200 mg qd as an alternative option to bictegravir or dolutegravir as INSTI plus 2 NRTIs switch in virologically suppressed patients.

Declarations

Ethics approval and consent to participate

The protocol was approved by the Ethics Committee of Est III (17.04.06), and authorized by the French National Agency for the Safety of Medicines (ANSM 170133A-41). All participants gave written informed consent.

Consent for publication: Not applicable

Data availability statement: The data that support the findings of this study are available from CHU Nantes but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of CHU Nantes.

Competing interests:

All authors declare that they have no competing interests in relation to this work.

Funding: The research department of Nantes University Hospital, monitored the study, collected and analysed the data. The authors had full access to the data and interpreted the results. The Nantes University Hospital was the promotor. This research was carried out with the support of MSD France. MSD France had no role in trial design, data collection, monitoring, management and analysis or writing of the manuscript.

Authors' contributions

NH, CA, AJ, AG and FR participated in the design of the study protocol and data collection. AG performed the data management and statistical analyses. NH, CA, CK, JMM, EC, FBS, LH, CD, DM, HH, EAG and FR enrolled patients in the study and contributed to follow-up. NH and FR wrote the first manuscript draft. All authors participated in interpretation of the data and writing of the final manuscript and all authors approved the final manuscript. FR was responsible for the overall supervision of the study.

Acknowledgments

We thank the QDISS study participants, as well as the caregivers and staff of all the centers taking part in the study. We thank the Nantes university hospital and his research department staff. We thank Martin Duracinsky who kindly provided the PROQOL HIV questionnaire.
Members of the QDISS study group (in addition to authors): Dr Olivier Bollengier, Dr Thomas Guimard, Dr Sophie Leautez (Centre hospitalier départemental de Vendée, La Roche sur Yon), Dr Sophie Blanchi (Centre hospitalier Le Mans), Dr Agathe Becker, Dr Laurent Cotte, Professor Tristan Ferry, Dr Thomas Perpoint, Dr Marie-Anne Trabaud (Hôpital Croix-Rousse, Lyon), Laetitia Biron, Professor Virginie Ferré, Dr Laurent Flet, Dr Véronique Reliquet, Audrey Rodalec, Christèle Volteau (CHU Hotel-Dieu, Nantes), Sophie Breaud, Dr Pascal Puglièse, Professor Eric Rosenthal (Hôpital L'Archet, Nice), Barbara De Dieuleveult, Dr Thierry Prazuck (CHR Orléans), Dr Antoine Bachelard, Sylvie Legac, Professor Yazdan Yazdanpanah (Hôpital Bichat-Claude Bernard, Paris), Professor Jade Ghosn, Myriam Kalambay, Dr Laurence Slama, Professor Jean-Paul Viard (Hôpital Hotel-Dieu, Paris), Dr Jérémy Lourenco (Hôpital Necker, Paris), Dr Nadine Ktorza, Dr Romain Palich, Dr Luminita Schneider (Hôpital Pitié-Salpêtrière, Paris), Dr Alexandre Aslan, Dr Mariagrazia Tateo, Dr Jeremy Zeggagh (Hôpital Saint-Louis, Paris), Dr Véronique Brodard, Dr Maxime Hentzien, Isabelle Kmiec, Dr Yohan N’Guyen (CHU Reims), Dr Faïza Ajana, Dr Laurence Bocket, Dr Thomas Huleux, Dr Agnes Meybeck (Hôpital Tourcoing).

References

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services; 2019. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf. Accessed May 1, 2021

2. Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2020;324:1651-1669.

3. Erlandson KM, Karris MY. HIV and aging: reconsidering the approach to management of comorbidities. Infect Dis Clin North Am. 2019;33:769-786.

4. Croxtall JD, Scott LJ. Raltegravir: in treatment-naive patients with HIV-1 infection. Drugs. 2010;70:631-642.

5. Cahn P, Kaplan R, Sax PE, et al. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. Lancet HIV. 2017;4:e486-494.

6. Woodcock A, Bradley C. Validation of the revised 10-item HIV Treatment Satisfaction Questionnaire status version and new change version. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2006;9:320-333.

7. Woodcock A, Bradley C. Validation of the HIV treatment satisfaction questionnaire (HIVTSQ). Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2001;10:517-531.
8. Duracinsky M, Lalanne C, Le Coeur S, et al. Psychometric validation of the PROQOL-HIV questionnaire, a new health-related quality of life instrument-specific to HIV disease. J Acquir Immune Defic Syndr. 2012;59:506-515.

9. Raffi F, Rachlis A, Stellbrink H-J, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381:735-743.

10. Lennox JL, DeJesus E, Lazzarin et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374:796-806.

11. Cahn P, Sax PE, Squires K, et al. Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial. J Acquir Immune Defic Syndr 1999. 2018;78:589-598.

12. Daar ES, DeJesus E, Ruane P, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018;5:e347-356.

13. Molina J-M, Ward D, Brar I, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV 2018;5:e357-365.

14. Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375:396-407

15. Martinez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS. 2010;24:1697-1707.

16. Elzi L, Erb S, Furrer H, et al. Adverse events of dolutegravir and raltegravir. AIDS2017;31:1853-1858.

17. Hoffmann C, Llibre JM. Neuropsychiatric events with dolutegravir and other integrase strand transfer inhibitors. AIDS Rev. 2019;21:4-10

18. Saumoy M, Sanchez-Quesada JL, Martinez, et al. LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy. Atherosclerosis 2012;225:200-207.
19. Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. *N Engl J Med.* 2019;381:803-815

20. Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. *Clin Infect Dis* 2020;71:1380-1389.

21. Lake JE, Wu K, Bares SH, et al. Risk factors for weight gain following switch to integrase inhibitor based antiretroviral therapy. *Clin Infect Dis* 2020;71:e471-477.

**Tables**

**Table: Baseline characteristics of the patients**
| Characteristic                                                                 | n = 100          |
|-------------------------------------------------------------------------------|------------------|
| Male, n (%)                                                                  | 77 (77)          |
| Age (years), median (IQR)                                                    | 47 (40-58)       |
| Origin, n (%)                                                                |                 |
|   Caucasian                                                                  | 61 (61%)         |
|   Sub-saharian africa                                                        | 32 (32%)         |
|   Others                                                                     | 7 (7%)           |
| Time since HIV diagnosis (years), median (IQR)                               | 10.3 (5-17)      |
| CDC classification, n (%)                                                     |                 |
|   A                                                                          | 62 (62%)         |
|   B                                                                          | 14 (14%)         |
|   C                                                                          | 24 (24%)         |
| CD4 nadir cell count (cells/mm$^3$), median (IQR), n = 99                    | 233 (122-372)    |
| CD4 cell count at screening (cells/mm$^3$), median (IQR)                     | 642 (473-875)    |
| Antiretroviral therapy duration (years), median (IQR)                        | 8.5 (4.7-14.5)   |
| Duration of last ARV therapy (years), median (IQR)                           | 3.3 (1.6-5.6)    |
| ARV therapy at screening, n (%)                                              |                 |
|   2 NRTIs + Protease inhibitor                                               | 40 (40%)         |
|   2 NRTIs + 1 NNRTI                                                          | 13 (13%)         |
|   2 NRTIs + 1 INSTI                                                          | 47 (47%)         |
|   2NRTIs + RAL BID                                                           | 32 (32%)         |
| Active hepatitis co-infection, n (%)                                         |                 |
|   Hepatitis B virus (Positive HBs Ag)                                        | 5 (5%)           |
|   Hepatitis C virus (Positive RNA)                                           | 0 (0%)           |
| BMI (kg/m$^2$), mean (±sd)                                                   | 26.6 (5.6)       |
| Creatinine (µmol/l), mean (±sd), n = 99                                      | 82 (±17.12)      |
| eGFR (MDRD) (mL/min), mean (±sd), n = 99                                     | 95.70 (±23.67)   |
| Total cholesterol (mmol/L), mean (±sd), n = 98                               | 4.76 (±0.95)     |
| LDL cholesterol (mmol/L), mean (±sd), n = 95                                 | 2.86 (±0.73)     |
| HDL cholesterol (mmol/L), mean (±sd), n = 96                                 | 1.32 (±0.54)     |
| Triglycerides (g/l) mean (±sd), n = 98                                       | 1.43 (±0.88)     |
| Glycaemia (mmol/L), mean (±sd), n = 85                                        | 5.33 (±1.28)     |

**Figures**
Figure 1

Study flow chart